Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747394 · ClinicalTrials.gov registry record · NA
Cognitive Training for Fragile X Syndrome
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT02747394 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 106 participants.
The verdict
NCT02747394, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
Individuals with fragile X syndrome (FXS) demonstrate profound executive function deficits that interfere with learning, socialization and emotion regulation. Extensive research focused on the animal models of FXS show that targeted pharmacological agents can normalize synaptic connectivity and reverse cognitive and behavioral deficits. This translational work has led to multiple national and international controlled trials in humans with FXS now underway. However, in contrast to the heavy focus on medication treatments, there have been no controlled trials to empirically-validate cognitive or behavioral interventions for FXS. The proposed study, the first non-pharmacological controlled trial for FXS, will evaluate the efficacy of Cogmed, a cognitive training program proven to enhance working memory and executive/frontal function in a variety of clinical populations. Demonstration of effective Cogmed training for FXS would represent a major advance in the field, one that may also generalize to other forms of intellectual disability. Furthermore, it is critical to determine whether the targeted pharmacological treatments can accelerate learning and cognitive development. Thus, the validation of Cogmed for FXS will provide a paradigm for testing hypotheses focused on combined efficacy of medication and cognitive training.
Interventions
- OTHER Working Memory Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-10-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02747394
The ClinicalTrials.gov registry entry for NCT02747394 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Working Memory Training is the first listed.
NCT02747394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02747394 about?
NCT02747394 is a clinical study titled "Cognitive Training for Fragile X Syndrome". Individuals with fragile X syndrome (FXS) demonstrate profound executive function deficits that interfere with learning, socialization and emotion regulation. Extensive research focused on the animal models of FXS show that targeted pharmacological agents can normalize synaptic connectivity and reve...
What is the current status of trial NCT02747394?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2013-01. Estimated completion is 2018-10-18.
What interventions are being tested in trial NCT02747394?
The interventions under investigation include: Working Memory Training (OTHER).
Who is sponsoring clinical trial NCT02747394?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.